There are also reports that B1R deficiency increases the susceptibility to DSS‐induced colitis and increases the production of cytokines in DSS‐induced colitis.[39] Pharmacological blockade of B1R did not alter the severity of DSS‐induced colitis, and B1R antagonists had no anti‐inflammatory or pro‐inflammatory effects on DSS‐induced colitis in mice, indicating that pharmacological blockade of B1R was insufficient to reduce the severity of DSS‐induced colitis in mice. This evidence concerns the gene BDKRB1 and colitis.